Table 1.
Patient Demographics
| Variable | TLC n=264 |
|---|---|
| Gender | |
| Male | 127 (48%) |
| Female | 137 (52%) |
| Age (years) | Mean = 29 (14-58) |
| 14-17 | 40 (15%) |
| 18-24 | 72 (27%) |
| 25-34 | 72 (27%) |
| 35-44 | 57 (22%) |
| 45-54 | 20 (7.6%) |
| 55-64 | 3 (1%) |
| Race | |
| White | 144 (56%) |
| Asian | 104 (40%) |
| Other | 11 (4%) |
| Chelator | |
| None | 22 (8.4%) |
| Deferoxamine (DFO, Desferal) | 57 (22%) |
| Deferasirox (DFX, Exjade) | 136 (52%) |
| Deferiprone (L1) | 9 (3.4%) |
| DFO/L1 | 21 (8%) |
| DFO/Exjade | 17 (6.5%) |
| Thalassemia Diagnosis | |
| B-thal regularly transfused1 | 204 (78%) |
| B-thal intermittently transfused2 | 24 (9%) |
| B-thal non-transfused3 | 2 (0.8%) |
| HbH CS | 4(1.5%) |
| EB-thal regularly transfused1 | 20 (7.6%) |
| EB-thal intermittently transfused2 | 6 (2.3%) |
| EB-thal non-transfused3 | 1 (0.4%) |
| alpha-thal | 2 (0.8%) |
| Transfusion Status4 | |
| Transfused | 224 (87%) |
| Non-Transfused | 33 (13%) |
| Location | |
| US | 193 (73%) |
| Canada | 36 (14%) |
| UK | 35 (13%) |
| Ferritin | Median 1371 (range 67-23,712) |
| Number of Secondary Complications | mean 1.7 (range 0-8) |
| 0 | 90 (34%) |
| 1 | 60 (23%) |
| 2 | 39 (15%) |
| 3 | 38 (14%) |
| 4 | 15 (5.7%) |
| 5 | 14 (5.3%) |
| 6 | 5 (1.9%) |
| 7 | 2 (0.76%) |
| 8 | 1 (0.38%) |
1
at least 8 transfusions in the past year
2
1-7 transfusions in the past year
3
no transfusions in the past year
4
in the past year